|
1
|
Aridgides PD, Movsas B and Bogart JA:
Thoracic radiotherapy for limited stage small cell lung carcinoma.
Curr Probl Cancer. 36:88–105. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
William WN Jr and Glisson BS: Novel
strategies for the treatment of small-cell lung carcinoma. Nat Rev
Clin Oncol. 8:611–619. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nickolich M, Babakoohi S, Fu P and Dowlati
A: Clinical trial design in small cell lung cancer: Surrogate end
points and statistical evolution. Clin Lung Cancer. 15:207–212.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Byers LA and Rudin CM: Small cell lung
cancer: Where do we go from here? Cancer. 121:664–672. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xiong S, Tu H, Kollareddy M, Pant V, Li Q,
Zhang Y, Jackson JG, Suh YA, Elizondo-Fraire AC, Yang P, et al:
Pla2g16 phospholipase mediates gain-of-function activities of
mutant p53. Proc Natl Acad Sci USA. 111:11145–11150. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nguyen GT, Schaefer S, Gertz M, Weyand M
and Steegborn C: Structures of human sirtuin 3 complexes with
ADP-ribose and with carba-NAD+ and SRT1720: Binding
details and inhibition mechanism. Acta Crystallogr D Biol
Crystallogr. 69:1423–1432. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guarente L: Introduction: Sirtuins in
aging and diseases. Methods Mol Biol. 1077:3–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang YY and Zhou LM: Sirt3 inhibits
hepatocellular carcinoma cell growth through reducing Mdm2-mediated
p53 degradation. Biochem Biophys Res Commun. 423:26–31. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Minamoto T, Buschmann T, Habelhah H,
Matusevich E, Tahara H, Boerresen-Dale AL, Harris C, Sidransky D
and Ronai Z: Distinct pattern of p53 phosphorylation in human
tumors. Oncogene. 20:3341–3347. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Warnock LJ, Raines SA and Milner J: Aurora
A mediates cross-talk between N- and C-terminal post-translational
modifications of p53. Cancer Biol Ther. 12:1059–1068. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rodriguez OC, Choudhury S, Kolukula V,
Vietsch EE, Catania J, Preet A, Reynoso K, Bargonetti J, Wellstein
A, Albanese C and Avantaggiati M: Dietary downregulation of mutant
p53 levels via glucose restriction: Mechanisms and implications for
tumor therapy. Cell Cycle. 11:4436–4446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pawelek JM, Low KB and Bermudes D:
Bacteria as tumour- targeting vectors. Lancet Oncol. 4:548–556.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Leary EM and Igdoura SA: The therapeutic
potential of pharmacological chaperones and proteosomal inhibitors,
Celastrol and MG132 in the treatment of sialidosis. Mol Genet
Metab. 107:173–185. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ashraf N, Zino S, Macintyre A, Kingsmore
D, Payne AP, George WD and Shiels PG: Altered sirtuin expression is
associated with node-positive breast cancer. Br J Cancer.
95:1056–1061. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiao K, Jiang J, Wang W, Cao S, Zhu L,
Zeng H, Ouyang R, Zhou R and Chen P: Sirt3 is a tumor suppressor in
lung adenocarcinoma cells. Oncol Rep. 30:1323–1328. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oberst A: Death in the fast lane: What's
next for necroptosis? FEBS J. 283:2616–2625. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pasparakis M and Vandenabeele P:
Necroptosis and its role in inflammation. Nature. 517:311–320.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Braicu C, Pileczki V, Irimie A and
Berindan-Neagoe I: p53siRNA therapy reduces cell proliferation,
migration and induces apoptosis in triple negative breast cancer
cells. Mol Cell Biochem. 381:61–68. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lim LY, Vidnovic N, Ellisen LW and Leong
CO: Mutant p53 mediates survival of breast cancer cells. Br J
Cancer. 101:1606–1612. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ali A, Wang Z, Fu J, Ji L, Liu J, Li L,
Wang H, Chen J, Caulin C, Myers JN, et al: Differential regulation
of the REGү-proteasome pathway by p53/TGF-β signalling and mutant
p53 in cancer cells. Nat Commun. 4:26672013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiong Y, Wang L, Wang S, Wang M, Zhao J,
Zhang Z, Li X, Jia L and Han Y: SIRT3 deacetylates and promotes
degradation of P53 in PTEN-defective non-small cell lung cancer. J
Cancer Res Clin Oncol. 144:189–198. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jethwa A, Słabicki M, Hüllein J, Jentzsch
M, Dalal V, Rabe S, Wagner L, Walther T, Klapper W; MMML Network
Project, ; et al: TRRAP is essential for regulating the
accumulation of mutant and wild-type p53 in lymphoma. Blood.
131:2789–2802. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tseng AH, Wu LH, Shieh SS and Wang DL:
SIRT3 interactions with FOXO3 acetylation, phosphorylation and
ubiquitinylation mediate endothelial cell responses to hypoxia.
Biochem J. 464:157–168. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hemelaar J, Lelyveld VS, Kessler BM and
Ploegh HL: A single protease, Apg4B, is specific for the
autophagy-related ubiquitin-like proteins GATE-16, MAP1-LC3,
GABARAP, and Apg8L. J Biol Chem. 278:51841–51850. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Boutouja F, Brinkmeier R, Mastalski T, El
Magraoui F and Platta HW: Regulation of the tumor-suppressor BECLIN
1 by distinct ubiquitination cascades. Int J Mol Sci. 18:E25412017.
View Article : Google Scholar : PubMed/NCBI
|
